- Trials with a EudraCT protocol (44,347)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
44,347 result(s) found.
Displaying page 1,374 of 2,218.
EudraCT Number: 2008-008259-41 | Sponsor Protocol Number: OZR-2008-20 | Start Date*: 2009-03-30 |
Sponsor Name:Rotterdam Eye Hospital | ||
Full Title: Anti-VEGF (bevacizumab/ranibizumab) versus RPE-choroid graft in the treatment of 1) non-responders to 3 intravitreal anti-VEGF injections, or 2) patients with AMD and pigment epithelium rip, or 3) ... | ||
Medical condition: Age related macular degeneration and either of the following conditions: 1) not responding to 3 intravitreal anti-VEGF injections, or 2) pigment epithelium rip, or 3) massive haemorrhage. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-013640-37 | Sponsor Protocol Number: V110_04 | Start Date*: 2009-07-31 |
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l. | ||
Full Title: A Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Cell-derived, Inactivated Novel Swine O... | ||
Medical condition: Pandemic influenza | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) NL (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-001414-25 | Sponsor Protocol Number: 205.417 | Start Date*: 2008-08-20 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat ® inhaler (5 μg/day) over 48 ... | |||||||||||||
Medical condition: Patients with severe persistent asthma who are still symptomatic despite being treated with high-dose inhaled corticosteroids and long-acting beta2-agonists. Additional asthma treatments are allowe... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017336-40 | Sponsor Protocol Number: 1235.33 | Start Date*: 2010-04-26 | |||||||||||||||||||||
Sponsor Name:Boehringer Ingelheim BV | |||||||||||||||||||||||
Full Title: Prospective, open label TElmisartan/AMlodipine single pill STudy to Assess the efficacy in patients with essential hypertension who are not controlled on RAASi mono-therapy being switched. | |||||||||||||||||||||||
Medical condition: Hypertension | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) IT (Completed) DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-019589-10 | Sponsor Protocol Number: HZA113091 | Start Date*: 2010-08-27 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Multicentre Study to assess efficacy and safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and Fluticasone Propionate FP)/Salm... | |||||||||||||
Medical condition: Persistent Asthma in Adults and Adolescents. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003227-20 | Sponsor Protocol Number: ZD4054 | Start Date*: 2007-09-27 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase III, Randomised, Double-blind Study to Assess the Efficacy and Safety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free... | |||||||||||||
Medical condition: hormone-resistant prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FI (Prematurely Ended) DE (Completed) BE (Completed) GB (Prematurely Ended) CZ (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) NL (Completed) FR (Completed) PT (Completed) DK (Prematurely Ended) HU (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005325-30 | Sponsor Protocol Number: D8180C00015 | Start Date*: 2008-04-25 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase II, Double-Blind, Placebo Controlled, Multi-Centre, Randomised Study of AZD0530 in Patients with Advanced Ovarian Cancer Sensitive to Platinum-Based Chemotherapy | |||||||||||||
Medical condition: advanced ovarian cancer sensitive to platinum based chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: NL (Completed) FR (Completed) DK (Completed) PT (Completed) BG (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001212-20 | Sponsor Protocol Number: 905-CL-057 | Start Date*: 2009-07-16 | |||||||||||
Sponsor Name:Astellas Pharma Europe B.V. | |||||||||||||
Full Title: An open-label, long term multi-center study to assess the safety and efficacy of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg, in male ... | |||||||||||||
Medical condition: Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) AT (Completed) IT (Completed) DE (Completed) FR (Completed) HU (Completed) SK (Completed) BE (Completed) CZ (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005335-94 | Sponsor Protocol Number: A6181078 | Start Date*: 2006-03-21 |
Sponsor Name:Pfizer, S.A. | ||
Full Title: A TREATMENT PROTOCOL FOR PATIENTS CONTINUING FROM A PRIOR SU011248 PROTOCOL Protocolo de continuación de tratamiento para pacientes provenientes de un protocolo previo con SU011248 | ||
Medical condition: Patients with any malignancy who have previously been evaluated in a SU001248 protocol | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) DE (Completed) NL (Completed) FR (Completed) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-016501-41 | Sponsor Protocol Number: 400-09-001 | Start Date*: 2010-06-29 |
Sponsor Name:Omrix Biopharmaceuticals Ltd | ||
Full Title: A Randomized, Controlled Study to Evaluate the Safety and Effectiveness of Evicel as an Adjunct to Sutured Dural Repair | ||
Medical condition: tissue adhesion/sealing and suture support in neurosurgery and surgical procedures where contact with cerebrospinal fluid or dura mater can occur e.g. otologic, rhinologic, ophthalmic and vertebral... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) BE (Completed) NL (Completed) FI (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-019791-73 | Sponsor Protocol Number: EFC11405 | Start Date*: 2010-07-22 | |||||||||||
Sponsor Name:Sanofi-aventis recherche & développement | |||||||||||||
Full Title: A randomized, double blind, placebo controlled, parallel group trial for assessing the clinical benefit of Dronedarone 400mg BID on top of standard therapy in patients with permanent atrial fibrill... | |||||||||||||
Medical condition: Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) SE (Prematurely Ended) FR (Prematurely Ended) CZ (Prematurely Ended) ES (Completed) HU (Completed) BE (Prematurely Ended) SK (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) FI (Prematurely Ended) AT (Prematurely Ended) DE (Completed) IT (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001093-11 | Sponsor Protocol Number: A6181030 | Start Date*: 2004-12-24 | |||||||||||
Sponsor Name:Pfizer Global Research and Development | |||||||||||||
Full Title: A Treatment Protocol for Patients Continuing from a Prior SU011248 Protocol | |||||||||||||
Medical condition: This is an open-label treatment protocol for patients who have participated in other SU011248 protocols to completion and are believed to have the potential to derive clinical benefit from SU011248... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Prematurely Ended) NL (Completed) SE (Completed) GR (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019427-58 | Sponsor Protocol Number: 400-10-001 | Start Date*: 2010-09-08 | |||||||||||
Sponsor Name:Omrix Biopharmaceuticals Ltd | |||||||||||||
Full Title: A Phase III Randomized, Controlled, Superiority Study Evaluating the Fibrin Pad Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Elective Hepatic Surgery | |||||||||||||
Medical condition: Subjects undergoing elective, open, hepatic surgery during which a resection plane is created and wherein an appropriate Target Bleeding Site is identified. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002957-22 | Sponsor Protocol Number: H80-MC-GWBR | Start Date*: 2008-03-13 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Efficacy of once weekly exenatide long acting release and once daily insulin glargine in patients with Type 2 diabetes treated with metformin alone or in combination with sulphonylurea. | |||||||||||||
Medical condition: Type 2 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) HU (Completed) BE (Completed) DK (Completed) GR (Completed) FR (Completed) CZ (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013766-78 | Sponsor Protocol Number: CA191-004 | Start Date*: 2010-04-14 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Phase I/II Trial of BMS-754807 in Combination with Trastuzumab (Herceptin®) in Subjects with Advanced or Metastatic Her-2-positive Breast Cancer Revised Protocol Number 01 (version 2.0, dated 0... | ||||||||||||||||||
Medical condition: Advanced or Metastatic Her-2-positive Breast Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: HU (Completed) GB (Completed) BE (Completed) NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-000155-34 | Sponsor Protocol Number: 2 79 52030 207 | Start Date*: 2008-06-02 | |||||||||||
Sponsor Name:Beaufour Ipsen Pharma | |||||||||||||
Full Title: PHASE IIIb, MULTICENTRE, OPEN-LABEL, SINGLE-ARM, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 mg ADMINISTERED EVERY 28 DAYS AS PRIMARY MEDICAL TREATMENT IN ACROMEGALIC PATIENTS... | |||||||||||||
Medical condition: ACROMEGALY ASSOCIATED WITH PITUITARY GLAND MACROADENOMA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) FR (Completed) ES (Prematurely Ended) SE (Completed) GB (Completed) BE (Completed) CZ (Completed) FI (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000480-27 | Sponsor Protocol Number: UCC-IGF-001 | Start Date*: 2011-06-03 | |||||||||||
Sponsor Name:University College Cork | |||||||||||||
Full Title: A Randomised Trial Evaluating the Safety and Efficacy of a Single Low Dose of Intracoronary Insulin-like Growth Factor-1 Following Percutaneous Coronary Intervention for ST-Elevation Acute Myocardi... | |||||||||||||
Medical condition: ST Elevation Myocardial Infarction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012820-97 | Sponsor Protocol Number: OSI-906-301 | Start Date*: 2009-12-29 | |||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma | |||||||||||||
Medical condition: Adrenocortical Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) FR (Completed) IT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005870-11 | Sponsor Protocol Number: CTKI258A2201 | Start Date*: 2010-02-18 | |||||||||||
Sponsor Name:Novartis Farmacéutica S.A. | |||||||||||||
Full Title: Estudio de fase II multicéntrico, no aleatorizado, abierto para explorar TKI258 en pacientes con carcinoma urotelial avanzado con FGFR3 mutado o FGFR3 natural | |||||||||||||
Medical condition: Pacientes con carcinoma urotelial avanzado con FGFR3 mutado o FGFR3 natural | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) AT (Completed) DE (Completed) IT (Completed) NL (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005492-94 | Sponsor Protocol Number: 28850 | Start Date*: 2009-04-30 | |||||||||||
Sponsor Name:MERCK SERONO SA | |||||||||||||
Full Title: OPEN LABEL TRIAL TO DETERMINE THE LONG TERM SAFETY OF SAFINAMIDE IN PARKINSON`S DISEASE PATIENTS | |||||||||||||
Medical condition: IDIOPATHIC PARKINSON`S DISEASE | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) BE (Completed) GB (Completed) AT (Completed) EE (Completed) ES (Completed) HU (Completed) NL (Completed) FR (Completed) SK (Prematurely Ended) CZ (Completed) FI (Completed) PT (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
